medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number S1

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (S1)

Hormonals contraceptives in dysfunctional uterine bleeding patients

Hernández-Marín I, Villegas-Rodríguez CM, Celis-González C

Language: Spanish
References: 24
Page: 163-177
PDF size: 262.63 Kb.


ABSTRACT

Abnormal uterine bleeding is a common disorder affecting 30% of women in reproductive age and has a significant impact on their quality of life: physical, social, emotional, sexual and financial. The cost of providing health services is equivalently high. Abnormal uterine bleeding in women of reproductive age is defined as bleeding from the uterine body, which is abnormal in terms of duration, volume, frequency and regularity, and which has persisted for six months. The International Federation of Gynecology and Obstetrics (FIGO) published in 2007 the first standardized program for the nomenclature and parameters of normal uterine bleeding (defined by the 5-95 percentiles based on epidemiological studies available on a large scale). This system was designed to create terms and definitions of normal uterine bleeding in the reproductive years that minimize ambiguity for evaluation. Nowadays, the system published in the year 2011 is used. Dysfunctional uterine bleeding is a diagnosis of exclusion. Establishing the treatment is complicated and variable, depending on the case. Although hysterectomy was the first option in the 1960s, medical treatment has evolved recently. The aim of this study is to review the role of contraceptives in the new forms of treatment of dysfunctional uterine bleeding.


REFERENCES

  1. Bradley LD, et al. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol 2016;214(1):31-44. https://doi.org/10.1016/j. ajog.2015.07.044

  2. Whitaker L, et al. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2016;34:54-65. https://doi. org/10.1016/j.bpobgyn.2015.11.012

  3. Hapangama DK, et al. Pathophysiology of heavy menstrual bleeding. Womens Health 2016;12(1):3-13. https://doi. org/10.2217/whe.15.81

  4. Busby G. Menstrual dysfunction. Obstet Gynaecol Reprod Med 2016;26(5):149-154. https://doi.org/10.1016/j. ogrm.2016.02.003

  5. Corbacioglu A. The management of dysfunctional uterine bleeding. Intechopen 2011. https://www.intechopen. com/books/update-on-mechanisms-of-hormone-actionfocus- on-metabolism-growth-and-reproduction/themanagement- of-dysfunctional-uterine-bleeding

  6. Töz E, et al. Comparison of classic terminology with the FIGO PALM-COEIN system for classification of the underlying causes of abnormal uterine bleeding. In J Gynaecol Obstet 2016;133(3):325-328. https://doi.org/10.1016/j. ijgo.2015.09.033

  7. Bandi ND, et al. Utility of the PALM-COEIN classification of abnormal uterine bleeding for Indian gynecologists. Int J Gynaecol Obstet 2016;133(2):196-198. https://doi. org/0.1016/j.ijgo.2015.09.030

  8. Munro MG. Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. Best Pract Res CLin Obstet Gynaecol 2017;40:3-22. https://doi.org/10.1016/j.bpobgyn. 2016.09.011

  9. Gupta J, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368(2):128-137. https://www.nejm.org/ doi/10.1056/NEJMoa1204724

  10. Motta T, et al. Dysfunctional uterine bleeding. Good Pract Pediatr Adol Gynecol 2017;99-115. https://doi. org/10.1007/978-3-319-57162-1_6

  11. Creatsas M, et al. Dysfunctional uterine bleeding during adolescence. Front Gynecol Endocrinol 2014;1:9-14. https://doi.org/10.1007/978-3-319-03494-2_2

  12. James AH. Heavy menstrual bleeding: work-up and management. Hematology Am Soc Hematol Educ Program 2016;2016(1):236-242. https://doi.org/10.1182/asheducation- 2016.1.236

  13. Smith RP. The physiology of menstruation. In: Dysmenorrhea and Menorrhagia. Springer, Cham 2018:1-17. https:// doi.org/10.1007/978-3-319-71964-1_1

  14. Maybin JA. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update 2015;21(6):748-761. https://doi.org/10.1093/humupd/ dmv038

  15. Benetti-Pinto CL. Abnormal uterine bleeding. Rev Bras Ginecol Obstet 2017;39(7):358-368. http://dx.doi. org/10.1055/s-0037-1603807

  16. Bahamondes L, et al. Recent advances in managing and understanding menstrual disorders. F1000Prime Pep 2015;7:33. http://f1000.com/prime/reports/m/7/33

  17. Sriprasert I, et al. Heavy menstrual bleeding diagnosis and medical management. Contracept Reprod Med 2017;2(1):20. https://doi.org/10.1186/s40834-017- 0047-4

  18. Jensen JT, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011;117:777-87. https://doi.org/10.1097/AOG.0b013e3182118ac3.

  19. Nappi RE, et al. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health 2014:6:711. https:// doi.org/10.2147/IJWH.S65481

  20. Polis RL, et al. Treatment options for the adolescent patient experiencing abnormal uterine bleeding. Curr Treatm Options Pediatr 2016;2(3):184-195. https://doi.org/10.1007/ s40746-016-0054-8

  21. Friedlander E, et al. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obst Gynecol Clin North Am 2015;42(4):593-603. https://doi.org/10.1016/j.ogc.2015.07.004

  22. Dhamangaonkar PC, et al. Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding. J Midlife Health 2015;6(1):26. https://doi.org/10.4103/0976- 7800.153615

  23. Gopimohan R, et al. A clinical study assessing the efficacy of a new variant of the levonorgestrel intrauterine system for abnormal uterine bleeding. Int J Gynecol Obstet 2015;129(2):114-117. https://doi.org/10.1016/j. ijgo.2014.11.023.

  24. Fraser IS, et al. Health-related quality of life and economic burden of abnormal uterine bleeding. Exp Rev Obstet Gynecol 2009;4(2):179-189. https://doi. org/10.1586/17474108.4.2.179




2020     |     www.medigraphic.com